Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT01186991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple-Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).
Study identification
- NCT ID
- NCT01186991
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Interventions
- Onartuzumab Drug
- Bevacizumab Drug
- Paclitaxel Drug
- Bevacizumab Placebo Drug
- Onartuzumab Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Mar 2016 (Actual)
- Completion
- Mar 2016 (Actual)
- Last update posted
- Jan 20, 2017
2011 – 2016
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood/Cancer Ctr | Bakersfield | California | 93309 | — |
| St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr | Fullerton | California | 92835 | — |
| Can Care Assoc Med Group Inc; Beach Cities Offices | Los Angeles | California | 90095-1772 | — |
| Univ of California Los Angeles | Los Angeles | California | 90095 | — |
| Kaiser Permanente Sacramento Medical Center | Sacramento | California | 95825 | — |
| Sharp Healthcare; Oncology Research Program | San Diego | California | 92123 | — |
| Kaiser Permanente - Vallejo | Vallejo | California | 94589 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists; SCRI | Fort Myers | Florida | 33916 | — |
| Suburban Hematology Oncology | Lawrenceville | Georgia | 30045 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214-3728 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute.. | Detroit | Michigan | 48201 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| North Shore Hem Onc Associates | East Setauket | New York | 11733 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Charleston Hematology Oncology | Charleston | South Carolina | 29414 | — |
| South Carolina Onc. Associate | Columbia | South Carolina | 29210 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| The Sarah Cannon Research Inst | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Northern Utah Associates | Ogden | Utah | 84403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01186991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01186991 live on ClinicalTrials.gov.